

Innova Captab Limited

April 17, 2026

Facilities/Instruments	Amount (₹ crore)	Rating ¹	Rating Action
Long-term bank facilities	426.72 (Enhanced from 389.38)	CARE A; Positive	Reaffirmed
Short-term bank facilities	40.00 (Enhanced from 20.00)	CARE A1	Reaffirmed

Details of instruments/facilities in Annexure-1.

The list of facilities / instruments falling under the purview of various financial sector regulators (FSRs), along with the names of respective FSRs has been disclosed under Annexure-7.

Rationale and key rating drivers

Reaffirmation of ratings assigned to bank facilities of Innova Captab Limited (ICL) continues to derive strength from the experienced promoters and their established track record in the pharmaceutical industry. Ratings further take comfort from the company's growing scale of operations, driven by sustained contribution across all business segments, which has continued in 9MFY26 (9M refers to April 01 to December 31) despite global headwinds. Ratings continue to factor in the company's comfortable financial risk profile, characterised by low overall gearing and healthy debt coverage indicators, and its internationally accredited manufacturing facilities, diversified product portfolio, and established relationship with reputed clients. However, ratings continue to remain constrained by profitability susceptible margins to raw material price volatility, regulatory risks, and intense competition in the contract development and manufacturing organisation (CDMO) segment.

Rating sensitivities: Factors likely to lead to rating actions

Positive factors

- Improvement in scale of operations by 20%, with profit before interest, lease rentals, depreciation, and taxation (PBILDT) margin remaining at a similar level, leading to improvement in debt coverage indicators.
- Improvement in total debt to PBILDT below 1.50x at the consolidated level on a sustained basis.

Negative factors

- Significant decline in scale of operations, including lower-than-envisaged ramp-up in operations of Sharon Bio-Medicine Limited (Sharon), with PBILDT margin consistently falling below 10% on a sustained basis, leading to deterioration in operational cash flows.
- Significant debt-funded capital expenditure or acquisition, other than envisaged, leading to total debt to PBILDT exceeding 2.00x on a sustained basis.

Analytical approach: Consolidated

CARE Ratings Limited (CareEdge Ratings) has considered a consolidated view of the financials of ICL, its subsidiaries and step-down subsidiary, considering common promoters and the presence of operational and financial linkages among the entities. List of consolidated entities is provided in Annexure-6.

Outlook: Positive

The "Positive" outlook reflects CareEdge Ratings' expectation of growth in the company's total operating income (TOI), supported by the ramp-up of the newly commissioned Jammu plant, repeat business from CDMO customers, and an increase in export sales. Debt coverage indicators are also expected to remain comfortable over the medium term, aided by stable profitability margins. However, the outlook may be revised to "Stable" if the company achieves lower-than-envisaged operational performance or there are delays in obtaining approvals from international regulatory authorities.

¹Complete definition of ratings assigned are available at www.careratings.com and other CARE Ratings Limited's publications.

Detailed description of key rating drivers:**Key strengths****Experienced promoters**

Incorporated in 2005, ICL is promoted by Manoj Kumar Lohariwala and Vinay Lohariwala. Both promoters have over two decades of experience in manufacturing and marketing pharmaceutical products. The promoters are actively involved in the day-to-day operations and are supported by a highly qualified and experienced team across domains.

Internationally accredited manufacturing facilities

The company's manufacturing facilities are accredited by leading regulatory authorities, including World Health Organization – Good Manufacturing Practices (WHO-GMP), European Union – Good Manufacturing Practices (EU-GMP), and United Kingdom – Medicines and Healthcare products Regulatory Agency (UK-MHRA). It also holds drug manufacturing licences for formulations from Himachal Pradesh State Drug Controlling and Licensing Authority.

Following the acquisition of Sharon, the group's exposure to regulated markets such as Canada, United Kingdom, Europe, and Australia has expanded. The company also has approvals to market products in semi-regulated countries such as Ghana, Nigeria, and Afghanistan. Timely receipt of regulatory approvals for the new Jammu plant remains a key monitorable.

Reputed client base and diversified product profile

The company has been engaged in contract manufacturing of pharmaceutical formulations since 2005, resulting in long-standing relationships with reputed domestic and international customers. In addition to contract manufacturing, it markets products under its own brands through its wholly owned subsidiary, Univentis Medicare Limited (UML). The company's product portfolio includes a wide range of dosage forms such as tablets, capsules, syrups, and injectables, catering to multiple therapeutic segments including anti-allergic, anti-diabetic, analgesic, anti-malarial, antibiotics, dietary supplements, steroids, and anti-inflammatory products.

The group's product mix was further diversified through the acquisition of Sharon, which is engaged in manufacturing formulations and active pharmaceutical ingredients (APIs). Sharon's portfolio primarily covers acute therapies, with an expanding presence in chronic therapies.

Improvement in operational performance

The consolidated TOI of the company improved by ~15% in FY25 (FY refers to April 01 to March 31) and stood at ₹1,249 crore compared to ₹1,086 crore in FY24, supported by continued growth in the CDMO business and contribution from Sharon. The number of CDMO customers increased to 200+ in FY25. Around 80% of CDMO revenue was contributed by customers associated with the company for over five years. In the branded generics segment, the company expanded its pharmacy network to over 2.2 lakh touchpoints. The domestic branded generics segment contributed 18% to the company's TOI in FY25, while 13% was derived from international branded generics. The company's total exports contributed ~26% of TOI in FY25 compared to ~23% in FY24.

The PBILDT margin has shown a growing trend in the last three fiscals, with a 58-basis point (bps) improvement in FY25 to 15.37% (PY: 14.79%). The improvement was driven by higher margins in Sharon, which has a major presence in exports to regulated markets and due to a better product mix. However, sustainability of margins depends on timely ramp-up in utilisation levels at the newly commissioned Kathua plant.

9MFY26: The company has reported TOI of ₹1,182.22 crore in 9MFY26 (9MFY25: ₹928.94 crore) and steady PBILDT margin of 15.53% (against 15.83% in 9MFY25). This growth in scale of operations is supported by improvement in product portfolio with the Baddi Plant receiving GMP compliance certificate from UK-MHRA. The company has also expanded their geographical presence in both domestic and international market for its branded generic portfolio.

Strong financial risk profile

The company's financial risk profile remained strong, with a comfortable overall gearing ratio of 0.36x as on March 31, 2025, compared to 0.30x as on March 31, 2024, supported by a strong tangible net worth base and low utilisation of working capital limits. The debt coverage indicators also remained comfortable and improved, marked by interest coverage ratio and total debt to gross cash accruals (GCA) of 79.81x and 2.00x, respectively, as on March 31, 2025, compared to 7.45x and 2.11x, respectively, as on March 31, 2024. The improvement in interest coverage is due to better margins and lower interest cost, as the company received interest subvention under the Central Government's New Central Sector Scheme and interest on the Jammu plant loan was capitalised.

Key weaknesses

Susceptibility of profitability margins to raw material prices

APIs, which are essential inputs in the production of pharmaceutical formulations, are prone to significant price volatility owing to supply–demand imbalances and import dependence. With material costs forming ~65% of the total income in FY25 and intense competition in the unpatented formulations segment, the company’s profitability margins remain vulnerable to such fluctuations. However, the company’s CDMO business operates on a cost pass-through model, which provides some mitigation against volatility in input prices.

Highly competitive and fragmented nature of the industry with inherent regulatory risk

The group is engaged in manufacturing generic formulations and contract-based pharmaceutical formulations. The industry is characterised by a high level of competition with presence of a large number of small and big players. Pharmaceutical industry is a closely monitored and regulated industry and as such there are inherent risks and liabilities associated with the products and their manufacturing. Regular compliance with product and manufacturing quality standards of regulatory authorities is critical for selling products across geographies.

Liquidity: Adequate

ICL has a scheduled repayment obligation of ₹26.88 Cr in FY26 which is projected to be met through sufficient projected cash accruals. It had a comfortable current ratio of 1.89x and free cash and bank balances of ₹65 crore as on March 31, 2025. The average utilisation of working capital limits remained low at ~27% in the 12-month period ended June 2025.

Environment, social, and governance (ESG) risks

ESG risks primarily arise from stringent regulatory and compliance requirements, particularly around product safety, quality, and waste management. Environmental risks stem from effluent discharge, chemical handling, and energy-intensive operations, while social risks relate to employee health and safety, access to medicines, and ethical marketing practices. Governance risks centre on adherence to global regulatory standards, data integrity, and transparent disclosures. Any lapse in these areas can lead to reputational damage, regulatory penalties, and disruption in business operations.

The company has filed its Business Responsibility and Sustainability Report with the BSE and NSE for FY25, and there is no record of non-compliance. As disclosed in its annual report, the company has implemented several governance and sustainability-related policies, including a Vigil Mechanism and Whistleblower Policy, Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI), Board Diversity Policy, Corporate Social Responsibility (CSR) Policy, and an ESG Policy. Collectively, these measures provide an appropriate framework for managing risks associated with ESG requirements.

Applicable criteria

[Consolidation](#)

[Definition of Default](#)

[Liquidity Analysis of Non-financial sector entities](#)

[Rating Outlook and Rating Watch](#)

[Manufacturing Companies](#)

[Pharmaceuticals](#)

[Financial Ratios – Non financial Sector](#)

[Short Term Instruments](#)

About the company and industry

Industry classification

Macroeconomic indicator	Sector	Industry	Basic industry
Healthcare	Healthcare	Pharmaceuticals & biotechnology	Pharmaceuticals

Incorporated in 2005, ICL is engaged in manufacturing pharmaceutical formulations since 2005. The formulations are manufactured on contract basis for both domestic and foreign pharmaceutical companies and had 200+ CDMO customers as on March 31, 2025. ICL is also engaged in exporting formulations to over 30 countries majorly in semi-regulated markets, such as Nigeria, Kenya, and Ethiopia, among others. The Innova Group currently operates five manufacturing facilities: two in Baddi, Himachal Pradesh; one in Kathua, Jammu and Kashmir; one in Dehradun, Uttarakhand; and one in Taloja, Maharashtra.

Consolidated financials:

Brief Financials (₹ crore)	March 31, 2024 (A)	March 31, 2025 (A)	9MFY26 (UA)
Total operating income	1,085.52	1,248.98	1,182.22
PBILDT*	160.60	191.95	183.69
Profit after tax (PAT)	94.35	128.26	102.83
Overall gearing (x)	0.30	0.36	NA
Interest coverage (x)	7.45	79.81	NA

A: Audited UA: Unaudited; NA: Not available; Note: these are latest available financial results

*PBILDT: Profit before interest, lease rentals, depreciation, and tax

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years: Annexure-2

Detailed explanation of covenants of rated instrument / facility: Annexure-3

Complexity level of instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned and Rating Outlook
Fund-based - LT-Term Loan		-	-	30/09/2032	243.72	CARE A; Positive
Fund-based - LT-Working Capital Limits		-	-	-	183.00	CARE A; Positive
Non-fund-based - ST-BG/LC		-	-	-	40.00	CARE A1

Annexure-2: Rating history for last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2026-2027	Date(s) and Rating(s) assigned in 2025-2026	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024
1	Fund-based - LT-Term Loan	LT	243.72	CARE A; Positive	-	1)CARE A; Positive (19-Sep-25)	1)CARE A; Stable (04-Sep-24)	1)CARE A-; Negative (27-Sep-23) 2)CARE A-(RWN) (30-May-23)
2	Fund-based - LT-Working Capital Limits	LT	183.00	CARE A; Positive	-	1)CARE A; Positive (19-Sep-25)	1)CARE A; Stable (04-Sep-24)	1)CARE A-; Negative (27-Sep-23) 2)CARE A-(RWN) (30-May-23)
3	Fund-based - ST-Working Capital Limits	ST	-	-	-	-	1)Withdrawn (04-Sep-24)	1)CARE A2+ (27-Sep-23) 2)CARE A2+ (RWN) (30-May-23)
4	Non-fund-based - ST-BG/LC	ST	40.00	CARE A1	-	1)CARE A1 (19-Sep-25)	1)CARE A1 (04-Sep-24)	1)CARE A2+ (27-Sep-23) 2)CARE A2+ (RWN) (30-May-23)

LT: Long term; ST: Short term

Annexure-3: Detailed explanation of covenants of rated instruments/facilities: Not applicable

Annexure-4: Complexity level of instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Term Loan	Simple
2	Fund-based - LT-Working Capital Limits	Simple
3	Non-fund-based - ST-BG/LC	Simple

Annexure-5: Lender details

To view lender-wise details of bank facilities please [click here](#)

Annexure-6: List of entities consolidated

Sr No	Name of the entity	Extent of consolidation	Rationale for consolidation
1	Univentis Medicare Limited	Full	Subsidiary
2	Univentis Foundation	Full	Subsidiary
3	Sharon Bio-Medicine Limited	Full	Subsidiary

Annexure-7: List of Facilities/Instruments and FSRs

As required by SEBI Circular dated February 10, 2026, to Credit Rating Agencies (CRAs), the list of activities or instruments falling under the purview of various FSRs, along with the names of respective FSRs, is being disclosed below:

Sr. No.	Facilities/Instruments Name	Regulator of the Instruments ²
1.	Listed / Proposed to be Listed Bonds / Debentures / Preference Shares (All Securities)	SEBI
2.	Unlisted / Proposed to be Unlisted Bonds / Debentures / Preference Shares (All Securities)	MCA
3.	Listed PTCs / Securitisation Notes (Originated by Entities Regulated by RBI) *	SEBI
4.	Listed PTCs / Securitisation Notes (Originated by Entities Not Regulated by RBI) *	SEBI
5.	Unlisted PTCs / Securitisation Notes (Originated by Entities Regulated by RBI) *	RBI
6.	Listed Commercial Paper and NCDs with Original Maturity Less Than 1 Year	RBI
7.	Unlisted Commercial Paper and NCDs with Original Maturity Less Than 1 Year	RBI
8.	Loan Facilities (Fund / Non-Fund Based) From Banks / NBFCs / NHB / FIs ^	RBI
9.	External Commercial Borrowings and Other Similar Borrowings	RBI
10.	Certificates of Deposit	RBI
11.	Fixed Deposits Raised by Banks, NBFCs, HFCs, FIs	RBI
12.	Fixed Deposits Raised by Corporates Other Than Banks, NBFCs, HFCs, FIs	MCA
13.	Inter Corporate Deposits / Loans Extended by Corporates	MCA
14.	Borrowing Programme ~	-
15.	Issuer Ratings #	-
16.	Credit Ratings for Capital Protection Oriented Schemes (By Mutual Funds and AIFs)	SEBI
17.	Credit Quality Ratings (CQRs) for Mutual Fund Schemes and Schemes of AIFs	SEBI
18.	Listed Security Receipts	SEBI
19.	Unlisted Security Receipts	RBI
20.	Independent Credit Evaluation (ICE)	RBI
21.	Expected Loss Ratings (For Loan Facilities (Fund / Non-Fund Based) from Banks / NBFCs / NHB / FIs)	RBI
22.	Expected Loss Ratings (Listed / Proposed to be Listed Bonds / Debentures / Preference Shares (All Securities))	SEBI

²SEBI: Securities and Exchange Board of India; RBI: Reserve Bank of India; MCA: Ministry of Corporate Affairs; IRDAI: Insurance Regulatory and Development Authority of India; PFRDA: Pension Fund Regulatory and Development Authority

Sr. No.	Facilities/Instruments Name	Regulator of the Instruments ²
23.	Expected Loss Ratings (Unlisted / Proposed to be Unlisted Bonds / Debentures / Preference Shares (All Securities))	MCA
24.	Unlisted PTCs / Securitisation Notes (Originated by Entities Not Regulated by RBI) *	Investor-side regulator such as IRDAI, PFRDA @

* Includes securitisation transactions involving assignee payout, acquirer's payout.

~ The rated instrument may involve issuance of different instruments such as debt securities (listed or otherwise), bank loans, commercial paper (listed or otherwise), etc. The regulator of the instrument may accordingly be SEBI, RBI or MCA and can only be determined upon issuance. In the press releases subsequent to issuance(s), CareEdge Ratings shall separately capture the rated quantum details along with names of respective regulators.

^ Includes bank facilities such as liquidity facility, second loss facility that are part of securitisation transactions.

There is no instrument being rated and hence, Regulator of the Instrument is not applicable. The rating scale and definitions are being followed as stipulated in SEBI Master Circular for CRAs.

@ These ratings were assigned during regulatory regime prior to introduction of SEBI CRA Circular dated February 10, 2026 and the investor side regulators have accordingly been included.

Note: For facilities / instruments falling under the purview of FSRs other than SEBI, the grievance / dispute redressal mechanisms and investor protection mechanisms provided by SEBI shall not be available.

Note on complexity levels of rated instruments: CareEdge Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.

Contact us

<p>Media Contact</p> <p>Mradul Mishra Director CARE Ratings Limited Phone: +91-22-6754 3596 E-mail: mradul.mishra@careedge.in</p> <p>Relationship Contact</p> <p>Ankur Sachdeva Senior Director CARE Ratings Limited Phone: 912267543444 E-mail: Ankur.sachdeva@careedge.in</p>	<p>Analytical Contacts</p> <p>Puneet Kansal Director CARE Ratings Limited Phone: 120-4452018 E-mail: puneet.kansal@careedge.in</p> <p>Sachin Mathur Associate Director CARE Ratings Limited Phone: 91-120-4452054 E-mail: sachin.mathur@careedge.in</p> <p>Rohit Bhatia Lead Analyst CARE Ratings Limited E-mail: Rohit.Bhatia@careedge.in</p>
--	--

About us:

Established in 1993, CareEdge Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the Reserve Bank of India. With an equitable position in the Indian capital market, CareEdge Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CareEdge Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CareEdge Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit. For more information: www.careratings.com

Disclaimer:

This disclaimer pertains to the ratings issued and content published by CARE Ratings Limited ("CareEdge Ratings"). Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. Any opinions expressed herein are in good faith and are subject to change without notice. The rating reflects the opinions as on the date of the rating. A rating does not convey suitability or price for the investor. The rating agency does not conduct an audit on the rated entity or an independent verification of any information it receives and/or relies on for the rating exercise. CareEdge Ratings has based its ratings/outlook on the information obtained from reliable and credible sources. CareEdge Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. The users of the rating should rely on their own judgment and may take professional advice while using the rating in any way. CareEdge Ratings shall not be liable for any losses that user may incur or any financial liability whatsoever to the user of the rating. The use or access of the rating does not create a client relationship between CareEdge Ratings and the user.

CAREEDGE RATINGS DISCLAIMS WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR OTHER WARRANTIES OR CONDITIONS, TO THE EXTENT PERMITTED BY APPLICABLE LAWS, INCLUDING WARRANTIES OF MERCHANTABILITY, ACCURACY, COMPLETENESS, ERROR-FREE, NON-INFRINGEMENT, NON-INTERRUPTION, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE OR INTENDED USAGE.

Most entities whose bank facilities/instruments are rated by CareEdge Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CareEdge Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. CareEdge Ratings does not act as a fiduciary by providing the rating. The ratings are intended for use only within the jurisdiction of India. The ratings of CareEdge Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades. CareEdge Ratings has established policies and procedures as required under applicable laws and regulations which are available on its website.

Privacy Policy applies. For Privacy Policy please refer to https://www.careratings.com/privacy_policy

© 2026, CARE Ratings Limited. All Rights Reserved.

This content is being published for the purpose of dissemination of information required as per applicable law and regulations and CARE Ratings Limited holds exclusive copyright over the same. Any reproduction, retransmission, modification, derivative works or use or reference to the contents, in whole, in part or in any form, is prohibited except with prior express written consent from CARE Ratings Limited.

**For detailed Rating Report and subscription information,
please visit www.careratings.com**